[go: up one dir, main page]

WO1996041608A3 - Pyrularia thionin containing immunotoxins and immunotoxin-like conjugates - Google Patents

Pyrularia thionin containing immunotoxins and immunotoxin-like conjugates Download PDF

Info

Publication number
WO1996041608A3
WO1996041608A3 PCT/US1996/008811 US9608811W WO9641608A3 WO 1996041608 A3 WO1996041608 A3 WO 1996041608A3 US 9608811 W US9608811 W US 9608811W WO 9641608 A3 WO9641608 A3 WO 9641608A3
Authority
WO
WIPO (PCT)
Prior art keywords
thionin
immunotoxin
human
cells
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/008811
Other languages
French (fr)
Other versions
WO1996041608A2 (en
Inventor
Leo P Vernon
Eppie D Rael
Sardar E Gasanov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THERA PRO
Original Assignee
THERA PRO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by THERA PRO filed Critical THERA PRO
Priority to AU59817/96A priority Critical patent/AU5981796A/en
Publication of WO1996041608A2 publication Critical patent/WO1996041608A2/en
Publication of WO1996041608A3 publication Critical patent/WO1996041608A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to an immunotoxin comprising a mouse antihuman-CD5 monoclonal antibody conjugated to the toxin Pyrularia thionin (P.) thionin. P. thionin is a small, highly stable, membrane active peptide which is toxic to some procaryotic and all eucaryotic cells tested to date. The P. thioninimmunotoxin displays a high degree of cytotoxicity and specificity. The P. thionin immunotoxin was cytotoxic towards T cells which express the CD5 antigen, yet showed no reactivity towards human B cells, human or sheep erythrocytes or mouse lymphocytes which do not express the human CD5 antigen.
PCT/US1996/008811 1995-06-07 1996-06-05 Pyrularia thionin containing immunotoxins and immunotoxin-like conjugates Ceased WO1996041608A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU59817/96A AU5981796A (en) 1995-06-07 1996-06-05 Pyrularia thionin containing immunotoxins and immunotoxin-li ke conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47979995A 1995-06-07 1995-06-07
US08/479,799 1995-06-07

Publications (2)

Publication Number Publication Date
WO1996041608A2 WO1996041608A2 (en) 1996-12-27
WO1996041608A3 true WO1996041608A3 (en) 1997-02-06

Family

ID=23905495

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/008811 Ceased WO1996041608A2 (en) 1995-06-07 1996-06-05 Pyrularia thionin containing immunotoxins and immunotoxin-like conjugates

Country Status (2)

Country Link
AU (1) AU5981796A (en)
WO (1) WO1996041608A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9926875D0 (en) 1999-11-12 2000-01-12 Microbiological Research Agenc Use of lytic toxins and toxin conjugates
AU2000275771B2 (en) * 2000-09-11 2006-06-29 Therapro Technologies, Inc. Thionin as an antineoplastic and immunostimulant
WO2019108863A1 (en) 2017-11-29 2019-06-06 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd5+ cells
WO2020023561A1 (en) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
US20230135930A1 (en) 2019-04-24 2023-05-04 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARCH. BIOCHEM. BIOPHYS., April 1985, Vol. 238, No. 1, VERNON et al., "A Toxic Thionin from Pyrularia Pubera: Purification, Properties and Amino Acid Sequence", pages 18-29. *
BIOCHIM. BIOPHYS. ACTA, 1994, Vol. 1198, BRINKMANN et al., "Immunotoxins Against Cancers", pages 27-45. *
BLOOD, 01 April 1990, Vol. 75, No. 7, BYERS et al., "Use of an Anti-Pan T-Lymphocyte Ricin A Chain Immunotoxin in Steroid-Resistant Acute Graft-Versus-Host Disease", pages 1426-1432. *
CANCER IMMUNOL. IMMUNOTHER., 1983, Vol. 15, IMAI et al., "Selective in Vitro Toxicity of Purothionin Conjugate to the Monoclonal Antibody 225.28S to a Human High-Molecular-Weight Melanoma-Associated Antigen", pages 206-209. *
CANCER IMMUNOL. IMMUNOTHER., 1993, Vol. 36, PORRO et al., "In Vitro and in Vivo Properties of an Anti-CD5-Momordin Immunotoxin on Normal and Neoplastic T Lymphocytes", pages 346-350. *
J. TOXICOL., 1992, Vol. 11, No. 3, VERNON L.P., "Pyrularia Thionin: Physical Properties, Biological Response and Comparison to Other Thionins and Cardiotoxin", pages 169-191. *

Also Published As

Publication number Publication date
WO1996041608A2 (en) 1996-12-27
AU5981796A (en) 1997-01-09

Similar Documents

Publication Publication Date Title
MY108519A (en) Novel antibodies reactive with human carcinomas.
EP0375562A3 (en) Monoclonal antibody to human carcinomas
NZ332625A (en) Concentrated antibody preparation containing greater than 100 mg/ml of the antibody
DE3479633D1 (en) Immunotoxin conjugates
WO1991007941A3 (en) Methods and compositions for the treatment of hodgkin's disease
IL132380A0 (en) Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods
AU8316701A (en) Anti-dual integrin antibodies, compositions, methods and uses
WO1998055150A8 (en) Txu-7-pap immunotoxin and use thereof
AU4485696A (en) Anti-cd 30 antibodies preventing proteolytic cleavage and release of membrane-bound cd 30 antigen
Ghetie et al. Chemical construction of immunotoxins
WO1996041608A3 (en) Pyrularia thionin containing immunotoxins and immunotoxin-like conjugates
DK0952853T3 (en) Conjugate comprising an active agent, a polypeptide and a polyether
IL83183A0 (en) Immunotoxins,their preparation and pharmaceutical compositions containing them
WO1997025071A3 (en) Immunoconjugate for the treatment of aids
DE3751319D1 (en) USE AND COMPOSITION TO IMPROVE THE "TARGETING" OF ANTIBODIES, ANTIBODY PARTS, AND CONJUGATES THEREOF.
Siegall et al. Cytotoxicity of chimeric (human-murine) monoclonal antibody BR96 IgG, F (ab') 2, and Fab'conjugated to Pseudomonas exotoxin
MIYAZAKI et al. Preparation of antibody (IgG)-ricin A-chain conjugate and its biologic activity
KR900005996A (en) Immunotoxins for the treatment or prevention of autoimmune diseases
IT1249051B (en) IMMUNOTOXIN FROM ANTI-CD5 MONOCLONAL ANTIBODIES
DE69941358D1 (en) AGAINST HIV-1 GP120 ENVELOPE GLYCOPROTEIN-TARGETED RECOMBINANT IMMUNOTOXIN
Schütt et al. Selective killing of human monocytes by an immunotoxin containing partially denatured mistletoe lectin I
LEONARD et al. Monoclonal antibodies to purified ricin A-chain: production and properties
Song et al. Selective killing of gastric cancer cells by monoclonal antibody conjugated with a chain of ricin
Nett et al. GnRH analogs for destroying gonadotrophs
IL80918A (en) Monoclonal antibodies cross-reactive and cross-protective against p.aeruginosa serotypes and pharmaceutical compositions and kits containing said antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA